Table 1.
Baseline characteristics of all included studies.
| Study/Year | Country | Cases/Controls | Biomarkers | STARD | QUADAS |
|---|---|---|---|---|---|
| Destro/2004 [41] | Italy | 24/100 | p16 | 21 | 12 |
| Zhang/2004 [48] | China | 44/20 | p16 | 18 | 8 |
| Wang/2004 [57] | China | 34/21 | p16 | 17 | 7 |
| Konno/2004 [31] | Japan | 78/94 | p16, APC, RARβ | 20 | 11 |
| Belinsky/2005 [39] | USA | 53/118 | p16, MGMT, RASSF1A, DAP, H-cadherin, PAX5 | 20 | 9 |
| Olaussen/2005 [32] | France | 20/17 | HOXA9, p16, MAGE | 17 | 8 |
| Cirincione/2006 [44] | Italy | 18/112 | RARβ, p16, RASSF1A | 15 | 7 |
| Wang/2006 [45] | China | 79/22 | FHIT, p16, RARβ | 20 | 10 |
| Liu/2006 [54] | China | 77/30 | MGMT | 18 | 8 |
| Belinsky/2006 [47] | USA | 98/92 | p16, PAX5, MGMT, DAPK, GATA, RASSF1ASFRP1, HLHPBETA3, IGFBP3HCAD, LAMC2 | 20 | 10 |
| Georgiou/2007 [30] | Greece | 80/40 | p16 | 16 | 9 |
| Hsu/2007 [5] | China | 82/37 | p16, RARβ | 16 | 7 |
| Liu/2008 [29] | China | 58/107 | p16 | 18 | 10 |
| Guo/2008 [53] | China | 100/50 | p16 | 16 | 7 |
| Van der Drift/2008 [33] | Netherlands | 28/68 | RASSF1A | 19 | 11 |
| Hu/2009 [51] | China | 42/25 | p16 | 16 | 9 |
| Ye/2010 [49] | China | 30/27 | RASSF1A | 16 | 7 |
| Zhang/2010 [49] | China | 82/25 | RASSF1A, p16, DAPK | 18 | 8 |
| Hwang/2011 [36] | Korea | 76/109 | HOXA | 20 | 9 |
| Song/2011 [28] | China | 42/9 | p16, MGMT | 17 | 8 |
| Zhang/2011 [52] | China | 41/15 | p16 | 17 | 9 |
| Hang/2011 [38] | China | 47/24 | FHIT | 20 | 8 |
| Sun/2012 [55] | China | 120/120 | p16, RASSF1A | 19 | 7 |
| Hubers/2012 [46] | The Netherlands | 53/47 | RASSF1A, APC, CYGB | 18 | 10 |
| Guzmán/2012 [14] | Chile | 26/33 | p16, CDH1, MGMT | 18 | 11 |
| Shin/2012 [42] | Korea | 65/30 | MAGE, p16 | 17 | 9 |
| Leng/2012 [35] | USA | 64/64 | p16, MGMT, DAPK, PAX5, GATA, Dal-1, PCDH20, Jph3, Kifla, SULF2, RASSFlA, GATA, Dab2, Dcr2, RASSF2, TCF2l | 20 | 11 |
| Leng/2012 [35] | USA | 40/90 | p16, MGMT, DAPK, PAX5, GATA, Dal-1, PCDH20, Jph3, Kifla, SULF2, CXCL, RASSFlA, Dab2, Dcr2, RASSF2, TCF2l | 20 | 11 |
| Pan/2013 [56] | China | 20/13 | p16 | 19 | 8 |
| Hubers/2014 [34] | The Netherlands | 20/31 | RASSF1A, APC, CYGB, 3OST, PRDM14, FAM19A4, PHACTR3 | 19 | 8 |
| Hubers/2014 [43] | The Netherlands | 98/90 | RASSF1A, APC, CYGB | 20 | 10 |
| Hubers/2014 [43] | The Netherlands | 60/445 | RASSF1A, APC, CYGB | 20 | 10 |
| Hubers/2015 [58] | The Netherlands | 73/86 | RASSF1A, APC, CYGB, 3OST2, PRDM14, FAM19A4, PHACTR3 | 21 | 11 |
| Hubers/2015 [58] | The Netherlands | 159/154 | RASSF1A, APC, CYGB, 3OST2, PRDM14, FAM19A4, PHACTR3 | 21 | 11 |
| Su/2016 [40] | China | 117/174 | RASSF1A, 3OST2, PRDM14 | 18 | 7 |
| Hulbert/2016 [37] | USA | 90/24 | SOX17, TAC1, CDO1, HOXA, ZFP42 | 16 | 9 |
STARD: Standards for reporting of diagnostic accuracy; QUADAS: Quality assessment of studies of diagnostic accuracy